Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF
Livestreamed Session
Livestreamed Session
Recorded Session
Recorded Session
Session is Ticketed (Must Register for Session through Registration)
Session is Ticketed (Must Register for Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session Feedback

Workshop

W20--Cutting-edge Clinical Trials: Insights & Updates | Room: Flex A (Level 2)

W20.2- A Phase II study (CLAIRAFLY®) evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of the DPP1 (CatC) inhibitor BI 1291583 in cystic fibrosis: Effects of CFTR modulator therapy use

Friday, October 24, 2025
10:15 AM - 12:15 PM PDT
Location: Flex A (Level 2)

    Speaker(s)

  • Marcus A. A. Mall, MD

    Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine